Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.243
Filter
Add more filters

Publication year range
1.
Nanotechnology ; 35(40)2024 Jul 16.
Article in English | MEDLINE | ID: mdl-38901412

ABSTRACT

Hyperpigmentation is a skin disorder characterized by excessive production of melanin in the skin and includes dyschromias such as post-inflammatory hyperchromias, lentigens, melasma and chloasma. Topical products containing depigmenting agents offer a less aggressive treatment option for hyperpigmentation compared to methods like chemical peels and laser sessions. However, some of these agents can cause side effects such as redness and skin irritation. Encapsulating these actives in nanosystems shows promise in mitigating these effects and improving product safety and efficacy. In addition, nanocarriers have the ability to penetrate the skin, potentially allowing for targeted delivery of actives to the affected areas. The most commonly investigated nanosystems are nanoemulsions, vesicular nanosystems and nanoparticles, in which different materials can be used to generate different compositions in order to improve the properties of these nanocarriers. Nanocarriers have already been widely explored, but it is necessary to understand the evolution of these technologies when applied to the treatment of skin hyperchromias. Therefore, this literature review aims to present the state of the art over the last 15 years on the use of nanosystems as a potential strategy for encapsulating depigmenting actives for potential application in cosmetic products for skin hyperchromia. By providing a comprehensive overview of the latest research findings and technological advances, this article can contribute to improving the care and quality of life of people affected by this skin condition.


Subject(s)
Drug Carriers , Humans , Drug Carriers/chemistry , Nanoparticles/chemistry , Hyperpigmentation/drug therapy , Skin Lightening Preparations/administration & dosage , Skin Lightening Preparations/chemistry , Skin/drug effects , Skin/metabolism
2.
Br J Dermatol ; 186(1): 142-152, 2022 01.
Article in English | MEDLINE | ID: mdl-34254291

ABSTRACT

BACKGROUND: Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. OBJECTIVE: To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. METHODS: A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. RESULTS: From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. CONCLUSIONS: Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.


Subject(s)
COVID-19 Vaccines , COVID-19 , 2019-nCoV Vaccine mRNA-1273 , BNT162 Vaccine , ChAdOx1 nCoV-19 , Cross-Sectional Studies , Female , Humans , Middle Aged , SARS-CoV-2 , Vaccination/adverse effects
3.
Nutr Metab Cardiovasc Dis ; 32(7): 1774-1783, 2022 07.
Article in English | MEDLINE | ID: mdl-35637087

ABSTRACT

BACKGROUND AND AIMS: The roles of sodium or iodine intake on the metabolic syndrome (MetS) etiology remain controversial. We evaluated the associations of 24 h urinary sodium and iodine with MetS among Mesoamerican children and their adult parents. METHODS AND RESULTS: We conducted a cross-sectional study among 217 school-age children and 478 parents from 9 Mesoamerican cities. Exposures were high 24 h urinary sodium excretion and concentration (>2000 mg/d or mg/L, respectively) and high 24 h urinary iodine excretion and concentration (≥300 µg/d or µg/L, respectively). In children, the outcome was a standardized metabolic score from five criteria analogous to the Adult Treatment Panel (ATP) III criteria. In adults, MetS was defined according to the ATP III criteria. We estimated adjusted mean differences in the metabolic risk score and adjusted prevalence ratios of MetS between exposure categories using multivariable regression. In children, high sodium concentration was associated with a 0.10 units (43% of a SD) higher score (P = 0.001) and high iodine concentration was related to a 0.09 units (39% of a SD) higher score (P = 0.009). Unexpectedly, high 24 h urinary volume was associated with a lower metabolic score. In adults, high 24 h sodium excretion was related to hypertension and high iodine concentration was related to increased MetS prevalence. CONCLUSION: High sodium and iodine concentrations, but not 24 h iodine excretion, are significantly associated with MetS in children, whereas high 24 h urinary volume is related to a decreased metabolic score. In adults, high iodine concentration tends to be related to increased MetS prevalence, but not 24 h iodine excretion.


Subject(s)
Iodine , Metabolic Syndrome , Adenosine Triphosphate , Adult , Child , Cross-Sectional Studies , Humans , Metabolic Syndrome/diagnosis , Metabolic Syndrome/epidemiology , Metabolic Syndrome/etiology , Parents , Sodium , Sodium Chloride, Dietary/adverse effects
4.
J Chem Phys ; 156(21): 214501, 2022 Jun 07.
Article in English | MEDLINE | ID: mdl-35676139

ABSTRACT

Soret effect and diffusion in triethylene glycol (TEG)-water mixtures were investigated as a function of concentration at 25 °C by means of optical digital interferometry, with the use of a classical Soret cell. Diffusion D, thermal diffusion DT, and Soret ST coefficients are described for the full concentration range and an analysis is made individually for TEG-water mixture and within a series of n-ethylene glycol (n-EG) aqueous systems. All coefficients decrease with increasing the concentration of TEG and n-EG. ST shows a change of sign with concentration, and this change is directly related to the ability of the n-EG molecule to establish hydrogen bonding with water. Diffusion and thermal diffusion coefficients present a plateau behavior with increasing concentration, showing the occurrence of changes in the preferential interactions in aqueous solution with concentration and meaning that, at high TEG composition, ether oxygens can be involved in the molecular interactions.


Subject(s)
Ethylene Glycol , Water , Diffusion , Polyethylene Glycols
5.
Anaesthesia ; 77(12): 1356-1367, 2022 12.
Article in English | MEDLINE | ID: mdl-36130834

ABSTRACT

Over 1.5 million major surgical procedures take place in the UK NHS each year and approximately 25% of patients develop at least one complication. The most widely used risk-adjustment model for postoperative morbidity in the UK is the physiological and operative severity score for the enumeration of mortality and morbidity. However, this model was derived more than 30 years ago and now overestimates the risk of morbidity. In addition, contemporary definitions of some model predictors are markedly different compared with when the tool was developed. A second model used in clinical practice is the American College of Surgeons National Surgical Quality Improvement Programme risk model; this provides a risk estimate for a range of postoperative complications. This model, widely used in North America, is not open source and therefore cannot be applied to patient populations in other settings. Data from a prospective multicentre clinical dataset of 118 NHS hospitals (the peri-operative quality improvement programme) were used to develop a bespoke risk-adjustment model for postoperative morbidity. Patients aged ≥ 18 years who underwent colorectal surgery were eligible for inclusion. Postoperative morbidity was defined using the postoperative morbidity survey at postoperative day 7. Thirty-one candidate variables were considered for inclusion in the model. Death or morbidity occurred by postoperative day 7 in 3098 out of 11,646 patients (26.6%). Twelve variables were incorporated into the final model, including (among others): Rockwood clinical frailty scale; body mass index; and index of multiple deprivation quintile. The C-statistic was 0.672 (95%CI 0.660-0.684), with a bootstrap optimism corrected C-statistic of 0.666 at internal validation. The model demonstrated good calibration across the range of morbidity estimates with a mean slope gradient of predicted risk of 0.959 (95%CI 0.894-1.024) with an index-corrected intercept of -0.038 (95%CI -0.112-0.036) at internal validation. Our model provides parsimonious case-mix adjustment to quantify risk of morbidity on postoperative day 7 for a UK population of patients undergoing major colorectal surgery. Despite the C-statistic of < 0.7, our model outperformed existing risk-models in widespread use. We therefore recommend application in case-mix adjustment, where incorporation into a continuous monitoring tool such as the variable life adjusted display or exponentially-weighted moving average-chart could support high-level monitoring and quality improvement of risk-adjusted outcome at the population level.


Subject(s)
Colorectal Neoplasms , Colorectal Surgery , Adult , Humans , Colorectal Surgery/adverse effects , Quality Improvement , Prospective Studies , Postoperative Complications/etiology , Morbidity , Colorectal Neoplasms/surgery , Risk Factors , Risk Assessment
6.
Zygote ; 30(5): 730-734, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35416145

ABSTRACT

This study evaluated the effect of fibroblast growth factor-2 (FGF-2) on the morphology, primordial follicle activation and growth after in vitro culture of domestic cat ovarian tissue. Ovaries (n = 12) from prepubertal domestic cats were collected and fragmented. One fragment was fixed for histological analysis (fresh control). The remaining fragments were incubated in control medium alone or with 10, 50 or 100 ng/ml FGF-2 for 7 days. After in vitro culture, the following endpoints were analyzed: morphology, activation by counting primordial and developing follicles, and growth (follicle and oocyte diameters). Treatment with 100 ng/ml FGF-2 maintained (P > 0.05) the percentage of normal follicles similar to fresh control. Follicle survival was greater (P < 0.05) after culture in 100 ng/ml FGF-2 than in 50 ng/ml FGF-2. The percentage of primordial follicles decreased (P < 0.05) and the percentage of developing follicles increased (P < 0.05) in all treatments compared with fresh tissue. The proportion of developing follicles increased (P < 0.05) in tissues incubated with 100 ng/ml FGF-2 compared with control medium and other FGF-2 concentrations. Furthermore, culture in 10 or 100 ng/ml FGF-2 resulted in increased (P < 0.05) follicle and oocyte diameters compared with fresh tissues and MEM+. In conclusion, FGF-2 at 100 ng/ml maintains follicle survival and promotes the in vitro activation and growth of cat primordial follicles.


Subject(s)
Fibroblast Growth Factor 2 , Ovarian Follicle , Animals , Cats , Female , Fibroblast Growth Factor 2/pharmacology , Oocytes/physiology , Ovarian Follicle/physiology , Ovary , Tissue Culture Techniques/methods
7.
Drug Chem Toxicol ; 45(5): 2003-2013, 2022 Sep.
Article in English | MEDLINE | ID: mdl-33685320

ABSTRACT

The diminazene aceturate (C14H15N7.2C4H7NO3) is a chemotherapeutic agent with more than six decades of use, however more studies regarding its toxicity still need to be performed. Thus, the present study determined the acute toxicity (14 days) of diminazene acetate (DIZE) in male and female swiss mice by changes in body mass, food consumption, biochemical and hematological parameters, locomotor activity and motor coordination. DIZE was administered at a single dose (1000 and 2000 mg/kg) orally. In addition, in vitro antioxidant capacity, hemolytic activity, toxicity in Artemia salina and in silico evaluation were also performed. The results obtained include several signs of toxicity (hypoactivity, loss of the straightening reflex and tachycardia), reduction of behavioral activity (locomotor activity and motor coordination) and significant changes (p < 0.05) in biochemical and hematological parameters. According to the in silico study, the DIZE can be classified based on the mean lethal dose (LD50) in category 4 (300 mg/kg < LD50 ≤ 2000 mg/kg, ProTox-II) or 3 (50 mg/kg < LD50 ≤ 300 mg/kg, AdmetSAR 1.0). Additionally, DIZE (30.3-969.9 nM) was not toxic to A. salina in the first 48 hours of treatment and was not cytotoxic to rat red blood cells after induced hemolysis. In vitro results indicated low antioxidant capacity against DPPH• and ABTS•+ radicals. Therefore, DIZE induces several adverse effects with influence on the central nervous system, changes in hematological and biochemical parameters and even mortality at the highest dose. However, absence of toxicity was observed in A. salina and rats red blood cells.


Subject(s)
Antiparasitic Agents , Diminazene , Angiotensin-Converting Enzyme 2 , Animals , Antioxidants , Antiparasitic Agents/therapeutic use , Diminazene/analogs & derivatives , Diminazene/toxicity , Female , Male , Mice , Peptidyl-Dipeptidase A , Rats , Rats, Wistar
8.
Water Sci Technol ; 85(5): 1538-1548, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35290230

ABSTRACT

Methane is a powerful greenhouse gas and a source of energy. Recovering this gas means lower greenhouse gas emission and potential reduction of energetic costs. The lack of full-scale results, the use of different methodologies to detect dissolved methane (d-CH4) and the fact that no process to remove d-CH4 from anaerobic effluents is energetically or economically viable at full-scale urged a different approach to the problem. To avoid methodological interference and facilitate comparison of results the Standard Test Method number D8028-17 published by ASTM International can be used to determine d-CH4. The use of real anaerobic reactor effluent also helps results to be compared. In this study, 80 samples from a full-scale anaerobic reactor showed an average concentration of dissolved methane of 14.9 mg·L-1, meaning an emission of 229 kg of CO2 eq·h-1 and an average of 113.5 kW wasted. Using spray nozzles, an alternative to the methods being researched, the average methane recovery was 11.5 mg·L-1 of CH4, an efficiency of 81.6%, meaning 177 kg of CO2 eq·h-1 emissions avoided and 87.9 kW of recoverable energy.


Subject(s)
Methane , Sewage , Anaerobiosis , Bioreactors , Waste Disposal, Fluid/methods
9.
Georgian Med News ; (330): 99-105, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36427851

ABSTRACT

Coronavirus disease 2019 (Covid-19) active cases continue to demand the development of safe and effective treatments. This is the first clinical trial to evaluate the safety and efficacy of oral thymic peptides. ; We conducted a nonrandomized phase 2 trial with a historic control group to evaluate the safety and efficacy of a daily 250-mg oral dose of thymic peptides in the treatment of hospitalized Covid-19 patients. Comparisons based on standard care from registry data were performed after propensity score matching. The primary outcomes were survival, time to recovery, and number of participants with treatment-related adverse events or side effects by day 20. ; A total of 44 patients were analyzed in this study: 22 in the thymic peptide group and 22 in the standard care group. There were no deaths in the intervention group compared to 24% mortality in standard care by day 20 (log-rank P=0.02). Kaplan-Meier analysis showed a significantly shorter time to recovery by day 20 in the thymic peptide group than in the standard care group (median, 6 days vs. 12 days; hazard ratio for recovery, 2.75 [95% confidence interval, 1.34 to 5.62]; log-rank P=0.002). No side effects or adverse events were reported. ; In patients hospitalized with Covid-19, the use of thymic peptides resulted in no side effects, adverse events, or deaths by day 20. Compared with the registry data, a significantly shorter time to recovery and mortality reduction were measured.


Subject(s)
COVID-19 Drug Treatment , Peptides , Humans , Honduras , Kaplan-Meier Estimate , Peptides/adverse effects , Proportional Hazards Models
10.
Int J Legal Med ; 135(2): 639-648, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32840664

ABSTRACT

The present study correlated the mineralization of third molars to chronological age using a modified classification based on Demirjian's stages in a Brazilian subpopulation and compared with the original classification. A total of 1082 patients with age ranging from 6 to 26 years were included in the sample, with at least one third molar on panoramic radiographs. The third molars were classified according to the original Demirjian classification (8 stages) and a new model based on the Demirjian method, where the original stages were grouped into four stages: AB-enamel mineralization; CD-crown dentin mineralization; EFG-root formation; and H-complete development. Statistical analyses were performed by Kruskal-Wallis/Dunn tests (α = 0.05) and the multinomial logistic regression model. Data were analyzed according to percentiles for the probability of an individual being over 18 years old. The mean ages of the stages in both classifications did not present a significant difference between superior and inferior arches (p < 0.05). The differences in mean ages between all the stages of mineralization were statistically significant (p < 0.001) only for the 4-stage classification. Males attained root formation and complete formation earlier than females (p < 0.05) in the 4-stage classification. The modified classification system showed dependence between chronological age and mineralization stages of third molars, simplifying the age estimation process. At stage H, females present a 95.7% chance of being over 18, while for males, this probability is 89.6%. This modified classification system simplifies the dental age estimation process based on third molars and can be used as a reference for future studies.


Subject(s)
Age Determination by Teeth/methods , Molar, Third/growth & development , Tooth Calcification , Adolescent , Adult , Brazil/epidemiology , Child , Dental Physiological Phenomena , Female , Humans , Male , Radiography, Panoramic , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL